Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-08-07
DOI
10.1038/s41598-019-47910-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer
- (2019) Samaresh Sau et al. Cancers
- Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
- (2018) Kristian M. Hargadon et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- PD-1 has a unique capacity to inhibit allergen-specific human CD4+ T cell responses
- (2018) Sandra Rosskopf et al. Scientific Reports
- Not All Immune Checkpoints Are Created Equal
- (2018) Annika De Sousa Linhares et al. Frontiers in Immunology
- Immuno-Oncology: Emerging Targets and Combination Therapies
- (2018) Henry T. Marshall et al. Frontiers in Oncology
- Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy
- (2018) Priyamvada Jayaprakash et al. JOURNAL OF CLINICAL INVESTIGATION
- Immunoregulatory functions of VISTA
- (2017) Elizabeth C. Nowak et al. IMMUNOLOGICAL REVIEWS
- A human monocytic NF-κB fluorescent reporter cell line for detection of microbial contaminants in biological samples
- (2017) Claire Battin et al. PLoS One
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
- (2017) Alice O. Kamphorst et al. SCIENCE
- A cellular platform for the evaluation of immune checkpoint molecules
- (2017) Sabrina Jutz et al. Oncotarget
- PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells
- (2017) Carmen Stecher et al. Frontiers in Immunology
- PD-1/PD-L and autoimmunity: A growing relationship
- (2016) Mohammad Reza Zamani et al. CELLULAR IMMUNOLOGY
- Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
- (2016) Toshio Shimizu et al. INVESTIGATIONAL NEW DRUGS
- Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-κB, NFAT and AP-1
- (2016) Sabrina Jutz et al. JOURNAL OF IMMUNOLOGICAL METHODS
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model
- (2016) Ana M. Contreras-Sandoval et al. Oncotarget
- Creation of an engineered APC system to explore and optimize the presentation of immunodominant peptides of major allergens
- (2016) Sandra Rosskopf et al. Scientific Reports
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
- (2015) Isabelle Le Mercier et al. Frontiers in Immunology
- Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than “Exhaustion” of Human CD8 T Cells
- (2013) Amandine Legat et al. Frontiers in Immunology
- PD-1 and BTLA and CD8+T-cell “exhaustion” in cancer
- (2012) Cara Haymaker et al. OncoImmunology
- T cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cells
- (2010) Judith Leitner et al. JOURNAL OF IMMUNOLOGICAL METHODS
- B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction
- (2009) Judith Leitner et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Interaction of human PD-L1 and B7-1
- (2008) Manish J. Butte et al. MOLECULAR IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now